HUTCHMED (China)

China And Japan Oncology Markets Will Broaden Opportunity Amidst Headwinds

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

21 Jul 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

UK£3.67

35.7% undervalued

15 Aug

UK£2.36

-10.3%

-2.9%

Author's Valuation

UK£3.7

35.7% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

UK£3.7

35.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.72%

Pharma revenue growth rate

0.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.82%

Calculation

US$155.60m

Earnings '28

34.03x

PE Ratio '28

US$5.30b

Market Cap '28

US$5.30b

Market Cap '28

874.05m

No. shares '28

US$6.06

Share Price '28

US$6.06 Share Price '28

Discounted to 2025 @ 6.82% p.a.

US$4.97

Fair Value '25

US$4.97 Fair Value '25

Converted to GBP @ 0.7387 USD/GBP Exchange Rate

UK£3.67

Fair Value '25